Hims & Hers Health Inc. Stock News

Shares of Hims & Hers (HIMS 1.74%) stock sank 17% this week, according to data from S&P Global Market Intelligence. The telehealth platform is delivering huge revenue growth but is at risk of a legal battle with weight loss drugmakers.

NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So what: If you purchased Hims common stock during the Class Period you may be ent...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310)...

The company reported quarterly financial results that underwhelmed investors in the stock market.

Explore the exciting world of Hims & Hers (HIMS -0.16%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

LOS ANGELES , Aug. 7, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK HERE BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD L...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE: HIMS) investors of a class action representing investors that bought securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"). Hims ...

Upgrading Hims & Hers Health, Inc. to a speculative Buy after a 20% post-earnings selloff, given management's reaffirmed guidance and near-term demand for personalized compounded GLP-1s. I believe the FY 2025 revenue guidance of $725 million hinges almost entirely on continued sales of personalized compounded GLP-1s. Key HIMS stock risks include potential FDA or court bans on compounded GLP-1s ...